Pharmaceutical Intermediates Market is Expected to Expected to Pegged around US$ 32,180 Mn by 2023, Due to Surge in Pharma Production Coupled with Increased Exports of API

According to Precision Business Insights, the Pharmaceutical Intermediates Market research report provides industry size and growth.

The Pharmaceutical Intermediates Market is anticipated to reach about USD 32,180 Mn by 2022, and anticipated to expand at a CAGR of 6.2 from 2023-2029. owing to surge in the production of pharmaceuticals coupled with the increased exports of APIs. Increased prevalence of chronic diseases will create demand for novel active pharmaceutical ingredients (API). Surge in the pharmaceutical production enables stimulate the demand for pharmaceutical intermediates. Moreover, Escalated exports of APIs will also enhance the demand for pharmaceutical intermediates. Pharmaceutical Intermediates market segmented on the basis of application, end-user and country

Cardiovascular Drugs Segment Expected to Dominate the Market:
Based on Application Type, The Pharmaceutical Intermediates market is segmented as anti-infective drugs, cardiovascular drugs, central nervous system drugs, anti-diabetic drugs, anti-ulcerants, and others. Cardiovascular drugs segment has been witnessed to account for major revenue share over the forecast period. The API intermediates are raw materials which are responsible for therapeutic action. These can be converted into the desired formulations such as capsules, tablets, and others.

Pharmaceutical Companies Will Dominate the Revenue Share:
Based on end-user type, pharmaceutical intermediates market segmented into pharmaceutical companies, research laboratories, contract manufacturing organizations, and others. The pharmaceutical companies are witnessed to account for major revenue share over the forecast period.

Asia-Pacific, Accounts for Major Revenue Share for Pharmaceutical Intermediates Market:
Precision Business Insights (PBI) Pharmaceutical Intermediates market report analyses the market in different regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa. According to regional analysis, Asia Pacific accounted for major revenue share due to increased R&D investments in China and India. Surge in the pharmaceutical production coupled with increased exports are witnessed to offer lucrative opportunities for the market players plunged in the pharmaceutical intermediates market. U.S. Pharmaceutical Intermediates market is accounted for major revenue share in North America, owing to increased pharmaceutical production and robust investments in R&D.

Strategic Collaborations & Exports Play Vital Role in Pharmaceutical Intermediates Market:
The increased R&D investment from pharmaceutical companies, research organizations and biotech companies are expected to create demand for pharmaceutical intermediates. Key player's profiles in the report are Aceto Corporation, BASF SE, Vertellus Holdings LLC, Lianhetech, Easter Chemical Corporation, Cycle Pharma Chem, Dishman Group, Dextra Laboratories Limited, Chemcon Specialty Chemical Pvt. Ltd, Midas Pharma GmbH, Codexis, A.R. Life Sciences Private Limited, Sanofi Winthrop Industries, and ZCL Chemical Ltd among others.

In January 2015, Johnson & Johnson partnered with Swiss biopharma AC Immune to develop a therapeutic vaccine for the development of anti-tau Alzheimers vaccine.

Technological advancements and strategic alliances are the key strategies adopted by market players:
According to Centers for Disease Control and Prevention (CDC) the global prevalence of Alzheimer's disease will triple among elderly patients, and the prevalence increases to 13.8 million by 2050. Lost patents of drug molecules and few more expected lose patents in near future, which is expected to create market opportunity for generic players. Majority of drugs in pipeline failed in the late stage of clinical trials, for instance, Eli Lilly's Solanezumab and Pfizer/Johnson & Johnson's Bapineuzumab have failed to prove the disease-slowing effects in the late-stage of clinical trials. Moreover, in 2014, FDA has approved cholinesterase inhibitors (Exelon, Aricept, and Razadyne) and memantine for the treatment of cognitive symptoms in Alzheimer disease. Researchers are considering new methods to treat Alzheimer's disease to address the Alzheimer's disease market needs. The current drugs in the market help mask the symptoms but they do not stop the progression of Alzheimer's disease. There are several promising drugs in developmental and testing stage for Alzheimer's disease, but researchers need more funding of research to ensure that fresh ideas continue to fill the pipeline. 

By Application Type
  • Anti-Infective Drugs
  • Cardiovascular Drugs
  • Central Nervous System Drugs
  • Anti-diabetic Drugs
  • Anti-Ulcerants
  • Others

By End-Users

  • Pharmaceutical Companies
  • Research Labs
  • Contract Manufacturing Organizations
  • Other Industries

About Precision Business Insights:
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact us :
Kemp House, 152-160 City Road,London EC1V 2NX
Email :
Toll Free (US) : +1-866-598-1553